Friday broker round-up UPDATE
7th Jun 2013 06:51
Aberdeeen Asset Management: Bank of America cuts target price from 475p to 410p downgrading to underperform. Anglo American: Nomura lowers target price from 1700p to 1650p and stays with its neutral rating. ARM Holdings: UBS moves target price from 950p to 970p, while its neutral rating remains un
Read moreThursday tips round-up: John Wood, RPC, Astra Zeneca
6th Jun 2013 10:24
The oil exploration sector has been battered by profit warnings and a perceived lack of orders in some territories, but John Wood Group is strong in deepwater engineering and in developed economies, while contracts tend to be on a less risky re-imbursable basis. In brief, that is the jist of a recen
Read moreLondon close: Stocks rise as Fed speculation continues
4th Jun 2013 16:55
Speculation surrounding the future of the Federal Reserve's stimulus programme continued to drive market sentiment on Tuesday as stocks rebounded on hopes that the US central bank will delay scaling back measures as it awaits a firmer recovery. The FTSE 100 rose 33 points (+0.51%) to 6,559 today af
Read moreLondon midday: Stocks gain on US stimulus hopes, UK construction data
4th Jun 2013 11:45
Hopes that the US Federal Reserve would delay pulling the plug on stimulus and a surprise return to growth in the UK construction sector gave markets a boost on Tuesday morning, with the FTSE 100 rebounding from a one-month low the day before. London's FTSE 100 fell to 6,525 on Monday, a level not
Read moreBroker tips: AstraZeneca, Serco, GKN
4th Jun 2013 11:03
Panmure Gordon has retained its 'hold' rating and 3,200p target price for biopharmaceuticals group AstraZeneca, saying that the news of the pull-out from fostamatinib should remind investors of the risks that the business carries. "Today's news of another phase III product opportunity slipping away
Read moreBroker snap: AstraZeneca needs to start delivering, says Panmure
4th Jun 2013 10:24
Panmure Gordon has retained its 'hold' rating and 3,200p target price for biopharmaceuticals group AstraZeneca, saying that the news of the pull-out from fostamatinib should remind investors of the risks that the business carries. Astra announced on Tuesday that it has decided not to pursue regulat
Read moreLondon open: Markets rebound as 'tapering' concerns ease
4th Jun 2013 09:10
Markets rebounded on Tuesday morning following a choppy session the day before as renewed hopes about US stimulus lifted sentiment early on. London's FTSE 100 lost 58 points yesterday, falling 0.9% to a one-month low of 6,525, after factory activity in both China and the US weakened in May. Manufac
Read moreLondon pre-open: Markets expected to rebound from one-month lows
4th Jun 2013 07:44
Following some heavy losses the day before on mixed manufacturing data worldwide, markets are expected to rebound slightly on Tuesday morning. London's FTSE 100 lost 58 points yesterday, falling 0.9% to a one-month low of 6,525, after factory activity in both China and the US weakened in May. Manuf
Read moreAstraZeneca takes impairment after pulling development of arthritis drug
4th Jun 2013 07:25
Biopharmaceuticals giant AstraZeneca will be hit by a one-off impairment charge after admitting that it has decided not to pursue a regulatory filing for fostamatinib, an oral drug it was hoping could be an alternative treatment for rheumatoid arthritis. After receiving mixed results from the OSKIR
Read moreFriday broker round-up UPDATE
31st May 2013 07:30
AstraZeneca: Citi increases target price from 3000p to 3500p, while leaving its neutral rating unchanged. Burberry: Morgan Stanley ups target price from 1300p to 1400p and leaves its equal-weight rating unchanged. Genel Energy: Credit Suisse shifts target price from 1236p to 1246p keeping an outpe
Read moreWednesday tips round-up: Sirius Minerals, Volex, GlaxoSmithKline
29th May 2013 06:54
The global pharmaceuticals sector is stuck in the 'doldrums' due to the impact of the so-called 'patent-cliff.' However, they have rebounded from their previous cycle lows - even in the case of laggards such as AstraZeneca, GlaxoSmithKline or Novartis - as investors seem to appreciate their defensiv
Read moreLondon close: Stimulus hopes drive triple-digit gains for FTSE 100
28th May 2013 16:49
While hopes have now faded for a long-term continuation of stimulus measures in the US, speculation surrounding continued monetary easing in Europe and Japan sparked a huge surge on equity markets on Tuesday. After reaching a 13-year high on Wednesday, the FTSE 100 dropped sharply in the latter par
Read moreLondon midday: Stocks bounce back after recent sell-off
28th May 2013 11:20
UK markets were registering impressive gains on Tuesday morning with hopes of continued monetary easing in the Eurozone lifting sentiment as stocks bounced back following last week's sharp sell-off. After reaching a 13-year high on Wednesday, the FTSE 100 dropped sharply in the latter part of last
Read moreLondon open: Stocks surge as markets play catch up after long weekend
28th May 2013 08:30
UK markets surged in early trading on Tuesday with traders wasting no time in playing catch up as they returned to their desks following the three-day weekend. After reaching a 13-year high on Wednesday, the FTSE 100 dropped sharply in the latter part of last week on fears of a scaling back of stim
Read moreLondon pre-open: Strong gains expected after long weekend
28th May 2013 07:25
Following last week's heavy losses, markets are expected to open with strong gains on Tuesday morning as traders in the UK and US return to their desks after a long weekend. City sources predict the FTSE 100 will open up over 60 points from Friday's close of 6,654. Senior Market Analyst Michael He
Read more